ROS1 and non-small cell lung carcinoma: Median overall survival (measured from the time of advanced non-resectable/metastatic disease diagnosis), median post-crizotinib overall survival and progression-free survival were 33.1 months, 16.2 months and 10.6 months, respectively (Figure 1a,b presents the comparison to select literature on crizotinib-treated ROS1-rearranged NSCLC patients).